Robert F. Ozols

Robert F. Ozols's AcademicInfluence.com Rankings

Robert F. Ozols

Philosophy

#5363

World Rank

#8134

Historical Rank

Logic

#2651

World Rank

#3669

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Robert F. Ozols's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Robert F. Ozols Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert F. Ozols's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. (2003) (1933)
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. (2007) (793)
The anthracycline antineoplastic drugs. (1981) (760)
Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology (2003) (674)
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. (1985) (585)
Ovarian cancer: screening, treatment, and followup. (1995) (579)
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. (1983) (545)
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. (1987) (524)
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). (2005) (425)
Reversal of adriamycin resistance by verapamil in human ovarian cancer. (1984) (417)
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. (1987) (411)
Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. (1985) (338)
High-dose cisplatin in hypertonic saline. (1984) (322)
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. (1995) (307)
Focus on epithelial ovarian cancer. (2004) (304)
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. (1988) (298)
Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. (1984) (267)
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. (1979) (264)
Treatment goals in ovarian cancer (2005) (259)
RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model (2007) (233)
Phase I and Pharmacological Studies of Adriamycin Administered Intraperitoneally to Patients with Ovarian Cancer (1982) (233)
Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. (1987) (220)
High-dose cisplatin in hypertonic saline in refractory ovarian cancer. (1985) (218)
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. (1987) (217)
Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. (1996) (209)
Systemic therapy for ovarian cancer: current status and new treatments. (2006) (191)
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. (1995) (191)
Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. (1984) (182)
A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. (1988) (181)
Advanced epithelial ovarian cancer: 1998 consensus statements. (1999) (180)
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer (1990) (179)
Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. (1984) (179)
Genes amplified and overexpressed in human multidrug-resistant cell lines. (1988) (173)
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. (1997) (172)
Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. (1989) (171)
Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. (1988) (169)
Chemotherapy of ovarian cancer. (1978) (165)
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. (1996) (156)
TRANSGENIC MICROALGAE AS GREEN CELL FACTORIES (2013) (154)
Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. (1986) (150)
Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. (1994) (138)
A Phase I and Pharmacokinetic Study of Diamminecyclobutanedicarboxylatoplatinum (NSC 241240) (1983) (137)
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. (1993) (135)
Cytogenetic studies in ovarian cancer. (1984) (133)
Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. (1986) (132)
High-dose carboplatin in refractory ovarian cancer patients. (1987) (131)
Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. (1994) (129)
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2006) (126)
Prevention and early detection of ovarian cancer: mission impossible? (2007) (124)
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. (1991) (123)
Reclassification of serous ovarian carcinoma by a 2‐tier system (2012) (120)
Advanced ovarian cancer correlation of histologic grade with response to therapy and survival (1980) (117)
Mechanisms of drug resistance in ovarian cancer (2010) (116)
Ovarian cancer biology. (1991) (115)
Mechanisms and modulation of resistance to chemotherapy in ovarian cancer (1993) (113)
Challenges for chemotherapy in ovarian cancer. (2006) (112)
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2006) (108)
Recurrent ovarian cancer: evidence-based treatment. (2002) (106)
Update on the management of ovarian cancer. (2002) (103)
Retinal toxicity after high-dose cisplatin therapy. (1985) (103)
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. (1992) (101)
Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. (1995) (101)
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. (1997) (100)
The measurement of cisplatin-DNA adduct levels in testicular cancer patients. (1988) (96)
Estrogen and Anti‐Estrogen Effects on the Growth of Human Epithelial Ovarian Cancer In Vitro (1989) (94)
Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. (1980) (93)
Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. (1997) (92)
Successful parenteral desensitization to paclitaxel. (1996) (91)
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. (1994) (90)
The management of recurrent ovarian cancer. (2007) (88)
High-dose cisplatin therapy in ovarian cancer. (1985) (86)
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182‐ICON5 (2003) (86)
Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. (1990) (86)
Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. (2007) (84)
Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. (1985) (83)
Cloning of Human Ovarian Cancer Cells in Soft Agar from Malignant Effusions and Peritoneal Washings (1980) (81)
Characterization of immunotoxins active against ovarian cancer cell lines. (1985) (81)
Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. (1990) (79)
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2008) (79)
Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. (1982) (78)
Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies (2003) (76)
Glutathione and drug resistance. (1996) (76)
High dose cisplatin and high dose carboplatin in refractory ovarian cancer. (1985) (72)
Chemotherapy for ovarian cancer. (1999) (68)
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. (1997) (66)
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. (2007) (66)
Chemotherapy of ovarian cancer. (1999) (66)
Ovarian cancer: new clinical approaches. (1991) (63)
Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. (1987) (62)
Peritoneoscopy in the management of ovarian cancer. (1981) (62)
Future directions in the treatment of ovarian cancer. (2002) (62)
Advanced epithelial ovarian cancer (1999) (60)
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. (2000) (60)
Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)--DNA adducts in cancer patients and animal models. (1985) (59)
PANCREATIC CANCER IN FATHER AND SON (1977) (59)
Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. (2006) (58)
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. (2011) (57)
Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. (2000) (56)
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma (2009) (56)
Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. (1979) (52)
Optimum chemotherapy for ovarian cancer. (2000) (51)
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. (2005) (51)
A randomized trial of cytoreductive surgery followed by chemotherapy versus chemotherapy alone in bulky stage III testicular cancer with poor prognostic features (1982) (50)
Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. (2000) (48)
Ovarian cancer. Clinical practice guidelines in oncology. (2008) (48)
Molecular and Clinical Advances in Anticancer Drug Resistance (2012) (48)
Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. (1996) (47)
Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines (1991) (45)
Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. (1997) (44)
The role of glutathione in drug resistance. (1990) (43)
Update of the NCCN ovarian cancer practice guidelines. (1997) (43)
Mechanisms of cross-resistance between radiation and antineoplastic drugs. (1988) (41)
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5 (2003) (41)
Histologic grade in advanced ovarian cancer. (1979) (41)
High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer. (1988) (40)
Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. (2003) (40)
Mechanisms of resistance to cisplatin and alkylating agents. (1989) (40)
Intraperitoneal chemotherapy for ovarian cancer. (2006) (38)
Ovarian cancer, Part II: Treatment. (1992) (38)
Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. (1986) (38)
New aspects of clinical drug resistance: the role of gene amplification and the reversal of resistance in drug refractory cancer. (1986) (38)
PROGNOSTIC VALUE OF PRETREATMENT CA-125 IN ADVANCED OVARIAN CARCINOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY (2009) (38)
Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. (1993) (38)
Clinical pharmacology of high-dose cisplatin (2004) (37)
Treatment of ovarian cancer: current status. (1994) (37)
The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics. (2002) (36)
Polythelia and testicular cancer. (1984) (35)
Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin. (1979) (35)
Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. (1995) (34)
A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). (1983) (34)
Ovarian cancer. Clinical practice guidelines in oncology. (2006) (34)
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. (1992) (33)
Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice. (1986) (33)
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. (2006) (32)
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5 (2003) (32)
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. (1999) (31)
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. (1992) (31)
Chemotherapy for advanced epithelial ovarian cancer. (1992) (30)
Drug Resistance in Cancer Therapy (2011) (30)
The Gynecologic Oncology Group experience in ovarian cancer. (1999) (30)
Clinical trials in ovarian carcinoma: study methodology. (2005) (30)
Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. (2006) (29)
Anticancer drug resistance : advances in molecular and clinical research (1994) (28)
Anticancer Drug Resistance (2012) (28)
Chemotherapy of advanced ovarian cancer: current status and future directions. (1997) (28)
Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin. (1986) (27)
Topotecan in Ovarian Cancer (1997) (27)
Cisplatin dose intensity. (1989) (27)
Manipulation of Cellular Thiols to Influence Drug Resistance (1988) (27)
Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. (1995) (26)
Carboplatin (JM-8) : current perspectives and future directions (1990) (26)
INDUCTION OF PROGESTERONE RECEPTOR WITH 17β-ESTRADI0L IN HUMAN OVARIAN CANCER (1984) (26)
Clinical reversal of drug resistance in ovarian cancer. (1993) (25)
Symptoms of ovarian cancer--where to set the bar? (2004) (25)
Effects of amphotericin B on adriamycin and melphalan cytotoxicity in human and murine ovarian carcinoma and in L1210 leukemia. (1983) (24)
High‐dose cisplatin for locally advanced or metastatic head and neck cancer. A phase ii pilot study (1989) (24)
Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. (1999) (24)
Pulmonary nodules resembling bronchioloalveolar carcinoma in adolescent cancer patients. (1988) (24)
The management of early ovarian cancer. (1995) (24)
Current status of chemotherapy for ovarian cancer. (1995) (23)
Pharmacologic reversal of drug resistance in ovarian cancer. (1985) (23)
Treatment of Poor Prognosis Nonseminomatous Testicular Cancer with a “High-Dose” Platinum Combination Chemotherapy Regimen (1984) (23)
Inhibitory effect of GnRH superagonist on the growth of human ovarian carcinoma NIH: OVCAR 3 in the nude mouse (1986) (23)
High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. (1993) (22)
Thrombocytopenia and extragonadal germ-cell neoplasm. (1984) (22)
DNA adducts of cisplatin in nucleated peripheral blood cells and tissues of cancer patients. (1987) (22)
The current role of gemcitabine in ovarian cancer. (2001) (22)
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. (2001) (22)
Update on Gynecologic Oncology Group (GOG) Trials in Ovarian Cancer (2004) (21)
Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. (1993) (21)
Ovarian cancer: where to next? (1991) (21)
Intraperitoneal chemotherapy in the management of ovarian cancer. (1985) (21)
Biologic therapy for the treatment of malignant common epithelial tumors of the ovary (1987) (20)
Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer. (1984) (20)
Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. (1993) (20)
Phase II study of topotecan in metastatic hormone-refractory prostate cancer (2004) (20)
Gemcitabine and carboplatin in second-line ovarian cancer. (2005) (19)
MVP (mitomycin, vinblastine, and progesterone): a second-line regimen in ovarian cancer with a high incidence of pulmonary toxicity. (1983) (18)
Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network. (1997) (18)
Topotecan, an active new antineoplastic agent: review and current status. (1997) (18)
The case for combination chemotherapy in the treatment of advanced ovarian cancer. (1985) (18)
ICON3 and chemotherapy for ovarian cancer (2002) (18)
Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer. (1995) (18)
Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. (1995) (17)
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens. (1991) (17)
Optimal dosing with carboplatin. (1989) (17)
Intraperitoneal treatment and dose-intense therapy in ovarian cancer. (1999) (17)
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer (1998) (17)
Identification of zinc finger mRNAs using domain-specific differential display. (1996) (17)
The role of gemcitabine in the treatment of ovarian cancer. (2000) (17)
Factoring outcomes in ovarian cancer. (1996) (16)
Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents. (2004) (16)
5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma. (1992) (16)
Drug resistance, supportive care and dose intensity (1993) (16)
Carboplatin and paclitaxel in ovarian cancer. (1995) (15)
Ovarian cancer: is dose intensity dead? (2007) (14)
Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (2012) (13)
High Dose Cisplatin in Hypertonic Saline: Renal Effects and Pharmacokinetics of a 40 MG/M2 QD × 5 Schedule (1984) (13)
Direct cloning of human ovarian cancer in soft agar: clinical limitations and pharmacologic applications. (1984) (13)
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. (2019) (12)
Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. (1994) (12)
Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer (1995) (12)
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience. (1995) (12)
Specific keynote: chemoprevention of ovarian cancer: the journey begins. (2003) (12)
Summary of symposium: Biology and therapy of ovarian cancer. (1991) (12)
NCCN Ovarian Cancer Practice Guidelines. The National Comprehensive Cancer Network. (1996) (12)
Induction of progesterone receptor with 17 beta-estradiol in human ovarian cancer. (1984) (12)
Phase I trial of 5-fluorouracil by 24-hour infusion weekly (1993) (11)
Future directions in the chemotherapy of ovarian cancer. (1997) (11)
Paclitaxel plus carboplatin in the treatment of ovarian cancer. (1999) (11)
High Dose Cisplatin and Drug Resistance: Clinical and Laboratory Correlations (1988) (11)
Progress in ovarian cancer (2003) (11)
Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC). (2000) (10)
Advanced ovarian cancer. Dose intensity. (1993) (10)
Role of chemotherapy in the future treatment of ovarian cancer (1992) (10)
Treatment of gynecologic cancer: the US experience. (1999) (10)
Intraperitoneal salvage chemotherapy in ovarian cancer: who is left to treat? (1992) (10)
Intraperitoneal therapy in ovarian cancer: time's up. (1991) (9)
Cancer epithelial de l'ovaire (stades evolues): Conference de consensus (1998) (2000) (9)
Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma. (1988) (9)
New developments with carboplatin in the treatment of ovarian cancer. (1992) (9)
Outcome issues in ovarian cancer. (1956) (9)
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. (2005) (9)
Current status of therapeutic modalities for treatment of gynecologic malignancies with emphasis on chemotherapy. (1981) (9)
Gemcitabine and carboplatin in combination: phase I and phase II studies. (1998) (8)
Anticancer drugs: effect on the cloning of Raji lymphoma cells in soft agar. (1982) (8)
Chemotherapy in advanced disease (1982) (8)
USA update on paclitaxel in ovarian cancer. (1995) (7)
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer (2004) (7)
Current status of staging laparotomy in colorectal and ovarian cancer. (1996) (7)
Cellular glutathione levels and sensitivity to radiation and antineoplastic agents in human ovarian cancer. (1988) (6)
Advanced ovarian cancer. Drug resistance, supportive care and dose intensity. (1993) (6)
Ovarian cancer. (1990) (6)
Estrogenic regulation and growth factor expression in human ovarian cancer (HOC) in vitro (1989) (6)
Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network. (1996) (6)
Advances in the chemotherapy of gynecologic malignancies (1992) (6)
[Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. (2000) (6)
Gynecologic oncology group trials in ovarian carcinoma. (1997) (6)
Drug resistance in ovarian cancer and potential for its reversal (1995) (5)
Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma. (1994) (5)
Radioimaging of human ovarian carcinoma xenograft in nude mice. (1986) (5)
Treatment of poor prognosis germ cell tumours with high dose cisplatin regimens. (1987) (5)
Phase I study of phosphonacetyl-l-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer (2004) (4)
Glutathione Depletion with Buthionine Sulfoximine: Potential Clinical Applications (1986) (4)
NICE Guidelines for Ovarian Cancer: Recommendations Versus Standard Care (2004) (4)
Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer. (1992) (4)
Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer (2010) (4)
Chemoprevention of ovarian cancer: The journey begins (2003) (4)
Controversies in the management of ovarian cancer (1997) (4)
Biomonitoring of cisplatin-DNA adducts in cancer patients receiving cisplatin chemotherapy. (1986) (4)
Therapeutic effect of a radiolabeled monoclonal antibody on human ovarian cancer xenograft in nude mice. (1989) (4)
Ovarian cancer : state of the art and future directions in translational research (2008) (3)
Potential therapeutic and diagnostic applications of the growth of testicular cancer in soft agar. (1983) (3)
Introduction to the Pre–International Gynecologic Cancer Society Roundtable Meeting: successful management of ovarian cancer (2005) (3)
Ovarian cancer clinical practice guidelines. (2004) (3)
Human ovarian cancer colony formation: growth from malignant washings and pharmacologic applications. (1980) (3)
Counterpoint: Intraperitoneal chemotherapy: an investigational treatment in ovarian cancer. (2004) (3)
Research directions in epithelial ovarian cancer. (1994) (3)
Ovarian cancer (oc): intraperitoneal (i.p.) Therapy with adriamycin (adr). Abstr. (1979) (3)
Phase I trial of buthionine sulfoximine (BSO) in combination with melphalan (1993) (3)
Modulation of drug resistance in human ovarian cancer: experimental results and clinical applications. (1986) (3)
The treatment of advanced stage ovarian carcinoma with a combination of chemotherapy, radiotherapy, and radiosensitizer: report of a pilot study from the National Cancer Institute. (1987) (3)
Cloning of human ovarian cancer cells in soft agar from malignant and peritoneal washings. (1980) (3)
Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer. (2008) (3)
Radiographic contribution to diagnosis and treatment of complications from peritoneoscopy (1981) (2)
Management of high risk patients with advanced testis cancer: National Cancer Institute approach. (1988) (2)
Evaluation ofin vitro drug screening leads using experimental models of human ovarian cancer (1992) (2)
High-performance liquid chromatographic determination of the S- and R-diastereoisomers of L-buthionine (SR)-sulfoximine in human plasma and urine. (1993) (2)
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. (1995) (2)
Phase II study of amonafide in advanced and recurrent sarcoma patients (1992) (2)
Chemotherapy drug resistance — a panel discussion (1987) (2)
A Phase II trial of weekly infusional 5-fluorouracil in combination with lowdose leucovorin in patients with advanced colorectal cancer (2004) (2)
High Dose Cisplatin with Hypertonic Saline: Toxicity and Therapeutic Results (1988) (2)
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (1995) (2)
Chemotherapy for ovarian cancer: beyond paclitaxel plus carboplatin. (1999) (2)
The Year book of oncology (1989) (2)
Characterization of a c/s-Diamrninedichloroplatinum(II)-resistant Human Ovarian Cancer Cell Line and Its Use in Evaluation of Platinum Analogues1 (2006) (2)
Role of carboplatin in ovarian cancer (1992) (2)
Poor prognosis germ cell tumors of the testes: improved results with high dose regimens. (1988) (1)
[Epithelial cancer of the ovary: current data]. (1993) (1)
Current concepts in cancer: ovary--treatment for stages III and IV. Chemotherapy in advanced disease. (1982) (1)
Intraperitoneal chemotherapy. (1984) (1)
Prevention and early detection of ovarian cancer (2007) (1)
Polyclonal Antibodies to Quantitate Cis (2016) (1)
ICON3 and chemotherapy for ovarian cancer. Authors' reply (2002) (1)
CARDIAC EFFECTS OF SUPRAPHARMACOLOGIC DOSES OF VERAPAMIL (1986) (1)
Ovarian cancer, part II: Treatment (1990) (1)
Testicular cancer. (1989) (1)
Murine ovarian cancer. A model for human disease. Abstr. (1978) (1)
Intraperitoneal Adriamycin in Ovarian Cancer (1982) (1)
Intracavitary chemotherapy in ovarian cancer-an investigational procedure. (1985) (1)
49 Paclitaxel (P) by 1 or 24 hour (HR) infusion combined with carboplatin (C) in advanced non-small cell lung carcinoma (NSCLC): A comparative analysis (1997) (1)
Multidrug resistance to alkylating agents and platinum compounds: state of our knowledge. (1990) (1)
Comprar Ovarian Cancer · State of the Art and Future Directions in Translational Research | Ozols, Robert | 9780387689661 | Springer (2008) (1)
Cisplatin–paclitaxel improves progression-free survival compared with cisplatin–cyclophosphamide in advanced epithelial ovarian cancer (2001) (1)
Future directions for paclitaxel (TAXOL) in the treatment of ovarian cancer. (1993) (1)
Phase II study of amonafide (Nafidamide, NSC 308847) in advanced colorectal cancer (1991) (1)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 4: Pharmacology and other tumor types. Puerto Rico, March 12-16, 1997. (1997) (1)
Double alkylator therapy (thiotepa plus chlorambucil) for previously treated advanced ovarian cancer. (1981) (1)
Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma (2004) (1)
Current Results and Therapeutic Issues (1989) (0)
Administered Intraperitoneally to Patients with Ovarian Cancer Phase I and Pharmacological Studies of Adriamycin (2006) (0)
Intraperitoneal Adriamycin and 5-Fluorouracil in Ovarian Cancer (1984) (0)
Role of chemotherapy dose intensification in the treatment of advanced ovarian cancer. Commentaries (1995) (0)
Cell Lines-Diamminedichloroplatinum ( II ) in Human Ovarian Cancer cis to Increased DNA Repair as a Mechanism of Acquired Resistance (2006) (0)
Ovarian cancer: To the editor (1987) (0)
Chemotherapy of advanced ovarian cancer. (1998) (0)
Cisplatin Resistance in Ovarian Cancer Cell Lines Cross-Resistance to Diverse Drugs Is Associated with Primary Updated Version (2006) (0)
Variable Baseline y-Glutamylcysteine Synthetase Messenger RNA Expression in Peripheral Mononuclear Cells of Cancer Patients, and Its Induction by Buthionine Sulfoximine Treatment1 (2006) (0)
Therapeutic effect of a radiolabeled monoclonal antibody (MAB) on ovarian cancer (1988) (0)
Ovarian Cancer: Diagnosis and Treatment (2002) (0)
Introduction. Ovarian Cancer (2006) (0)
Chemotherapy of ovarian cancer. (1998) (0)
Modulation of glutathione and associated enzymes as a therapeutic strategy (1991) (0)
Gynecologic cancer: Editorial overview (1989) (0)
Change in patient weight during platinum/paclitaxel-based chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. (2006) (0)
Abstract IA12: Ovarian cancer: Time for a new paradigm (2013) (0)
Counterpoint: Is There Still a Role for Intraperitoneal Platinum Therapy in Ovarian Cancer? There Is No Role for IP Chemotherapy in Ovarian Cancer. (2018) (0)
Phase I T rial o f M ultiple C ycles o f H igh-Dose C arboplatin, Paclitaxel, a nd T opotecan W ith P eripheral-Blood S tem- Cell S upport a s F ront-Line T herapy (2001) (0)
Drug Resistance in Cancer (1989) (0)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 3: Breast Cancer. Puerto Rico, March 12-16, 1997. Proceedings. (1997) (0)
Commentary (Ozols): Role of Chemotherapy Dose Intensification in the Treatment of Advanced Ovarian Cancer (1995) (0)
Commentary (Ozols): Neoadjuvant Chemotherapy for Ovarian Cancer (2005) (0)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Lung Cancer. Puerto Rico, March 12-16, 1997. (1999) (0)
The impact of chemotherapy dose density among obese patients with ovarian cancer: A novel assessment of drug dosage relative to patient body surface area (2014) (0)
Commentary (Ozols): Management of Ovarian Cancer (2006) (0)
Modification by Buthionine Sulfoximine and-resistant Human Ovarian Cancer Cell Lines and Their Radiation Survival Parameters of Antineoplastic Drug-sensitive Updated (2006) (0)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. St. Thomas, U.S.Virgin Islands, March 25-29, 1998. Proceedings and abstracts. (1999) (0)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 2: Gynecologic and Genitourinary Malignancies. Puerto Rico, March 12-16, 1997. (1997) (0)
Paclitaxel (Taxol®) plus carboplatin as first-line treatment for advanced ovarian cancer (1996) (0)
Intravenous chemotherapy with carboplatin/paclitaxel is the standard of care for patients with optimally resected stage III ovarian cancer (2006) (0)
Ovarian Cancer: Current Status and Future Directions (2000) (0)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 4: Breast Cancer II. Marrakech, Morocco, January 18-20, 1996 and St Croix, US Virgin Islands, March 13-16, 1996. (1997) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert F. Ozols?

Robert F. Ozols is affiliated with the following schools:

New York University